180 related articles for article (PubMed ID: 22952347)
1. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
3. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
4. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
5. Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
[TBL] [Abstract][Full Text] [Related]
6. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Hoey T; Yen WC; Axelrod F; Basi J; Donigian L; Dylla S; Fitch-Bruhns M; Lazetic S; Park IK; Sato A; Satyal S; Wang X; Clarke MF; Lewicki J; Gurney A
Cell Stem Cell; 2009 Aug; 5(2):168-77. PubMed ID: 19664991
[TBL] [Abstract][Full Text] [Related]
7. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
8. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
9. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells.
Harjes U; Bridges E; McIntyre A; Fielding BA; Harris AL
J Biol Chem; 2014 Aug; 289(33):23168-23176. PubMed ID: 24939870
[TBL] [Abstract][Full Text] [Related]
11. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
13. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
Zhou R; Wang S; Wen H; Wang M; Wu M
Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
[TBL] [Abstract][Full Text] [Related]
14. Delta-like 4/Notch signaling promotes Apc
Badenes M; Trindade A; Pissarra H; Lopes-da-Costa L; Duarte A
BMC Cancer; 2017 Jan; 17(1):50. PubMed ID: 28086833
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function.
Williams CK; Li JL; Murga M; Harris AL; Tosato G
Blood; 2006 Feb; 107(3):931-9. PubMed ID: 16219802
[TBL] [Abstract][Full Text] [Related]
16. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer.
Li J; Han R; Li J; Zhai L; Xie X; Zhang J; Chen Y; Luo J; Wang S; Sun Z; Cao Y; Lin L; Yang Q
Biomed Res Int; 2021; 2021():8875503. PubMed ID: 33628824
[TBL] [Abstract][Full Text] [Related]
18. Feed-forward signaling by membrane-bound ligand receptor circuit: the case of NOTCH DELTA-like 4 ligand in endothelial cells.
Caolo V; van den Akker NM; Verbruggen S; Donners MM; Swennen G; Schulten H; Waltenberger J; Post MJ; Molin DG
J Biol Chem; 2010 Dec; 285(52):40681-9. PubMed ID: 20959466
[TBL] [Abstract][Full Text] [Related]
19. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
[TBL] [Abstract][Full Text] [Related]
20. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Yen WC; Fischer MM; Axelrod F; Bond C; Cain J; Cancilla B; Henner WR; Meisner R; Sato A; Shah J; Tang T; Wallace B; Wang M; Zhang C; Kapoun AM; Lewicki J; Gurney A; Hoey T
Clin Cancer Res; 2015 May; 21(9):2084-95. PubMed ID: 25934888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
